TY - JOUR
T1 - Newly diagnosed multiple myeloma
T2 - How many drugs are enough?
AU - Kumar, Shaji K.
N1 - Publisher Copyright:
© 2021 Harborside Press. All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - The treatment of multiple myeloma (MM) has evolved over the past decade, yet it remains a chronic disease. Several trials of 4-drug induction regimens have resulted in deepening of disease response.With the emergence of multidrug regimens, questions have arisen regarding the role of autologous stem cell transplant (ASCT) in MM therapy and available treatment options after ASCT. Clinicians have also continued to improve the efficacy of maintenance therapies. In transplant-ineligible patients, the phases of treatment are less distinct; however, several regimens have demonstrated efficacy in this clinical setting. Future research should focus on individualizing treatment approaches.
AB - The treatment of multiple myeloma (MM) has evolved over the past decade, yet it remains a chronic disease. Several trials of 4-drug induction regimens have resulted in deepening of disease response.With the emergence of multidrug regimens, questions have arisen regarding the role of autologous stem cell transplant (ASCT) in MM therapy and available treatment options after ASCT. Clinicians have also continued to improve the efficacy of maintenance therapies. In transplant-ineligible patients, the phases of treatment are less distinct; however, several regimens have demonstrated efficacy in this clinical setting. Future research should focus on individualizing treatment approaches.
UR - http://www.scopus.com/inward/record.url?scp=85120634065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120634065&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2021.5104
DO - 10.6004/jnccn.2021.5104
M3 - Article
AN - SCOPUS:85120634065
SN - 1540-1405
VL - 19
SP - 1347
EP - 1350
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
ER -